Evaluating CMV Infection and Reactivation after Emapalumab: A Retrospective Evaluation of Letermovir Prophylaxis (TCT-ASTCT-CIBMTR 2026) - Jan 8, 2026 - Abstract #774; 581; Pres time: Feb 5, 2026; 06:30 PM - 08:00 PM; Location: Hall AB (Salt Palace Convention Center); "3. Assess the safety of CMV prophylaxis in patients receiving emapalumab."
Retrospective data • Cytomegalovirus Infection • Hemophagocytic lymphohistiocytosis • Immunology • Infectious Disease • Rare Diseases • IFNG
|
|
Chelsey Ivy; Graham Klink; Ashley Teusink-Cross; Michael Grimley
|